Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20354665 | 1.00 | MAOB (0.40) | MAOBACHEAKT1ALKNTRK2 | |
| SCHEMBL24223347 | 1.00 | MAOB (0.40) | MAOBACHEAKT1ALKNTRK2 | |
| SCHEMBL9463700 | 0.85 | ACHE (0.42) | MAOBACHEAKT1PGR | |
| SCHEMBL30295541 | 0.80 | ALK (0.34) | MAOBACHEALKNTRK2PGR | |
| SCHEMBL25261284 | 0.78 | TYMS (0.42) | AKT1 | |
| SCHEMBL2729079 | 0.78 | PBRM1 (0.42) | AKT1HTR2A | |
| SCHEMBL31042456 | 0.78 | TYMS (0.42) | AKT1 | |
| SCHEMBL23909108 | 0.78 | MAOB (0.40) | MAOB | |
| SCHEMBL3762755 | 0.78 | MAOB (0.40) | MAOB | |
| SCHEMBL25312082 | 0.78 | TYMS (0.42) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276319-A | Synthetic method of Laolatinib intermediate | 滁州学院 | 2022-04-05 | — | — | CN | claimed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| CN-114276319-B | Synthesis method of loratidine intermediate | 滁州学院 | 2023-11-03 | — | — | CN | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-111943885-B | Synthesis method of Laratinib intermediate 2-amino-5-bromo-3-hydroxypyridine | 西华大学 | 2023-08-04 | — | — | CN | disclosed |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| CN-114276319-A | Synthetic method of Laolatinib intermediate | 滁州学院 | 2022-04-05 | — | — | CN | disclosed |
| CN-109134410-B | Synthesis method of 5-fluoro-3-methylisobenzofuran-1 (3H) -ketone | 沈阳药科大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-112921057-A | Preparation method of Laratinib key intermediate | 上海天慈国际药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-112921057-A | Preparation method of Laratinib key intermediate | 上海天慈国际药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-112899321-A | Preparation method of Laratinib key intermediate | 上海天慈国际药业有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-111943885-A | Synthetic method of Laolatinib intermediate 2-amino-5-bromo-3-hydroxypyridine | 西华大学 | 2020-11-17 | — | — | CN | disclosed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MAOB 1999/4885ACHE 3493/4885AKT1 4688/4885 |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | MAOB 1999/4885ACHE 3493/4885AKT1 4688/4885 |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | MAOB 1999/4885ACHE 3493/4885AKT1 4688/4885 |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MAOB 1999/4885ACHE 3493/4885AKT1 4688/4885 |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MAOB 1999/4885ACHE 3493/4885AKT1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.